Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing antibody, according to six-month data from an open-label clinical trial. The Phase 2/3 Vibrance-MG study…
Two doses of inebilizumab, Amgen’s antibody-based therapy, led to sustained reductions in the severity of generalized myasthenia gravis (gMG) among patients for up to six months, meeting the primary goal of an ongoing Phase 3 clinical trial. The trial, called MINT (NCT04524273), demonstrated that inebilizumab’s benefits extend…
Descartes-08, an investigational CAR T-cell therapy for generalized myasthenia gravis (gMG), markedly reduced disease activity among patients who completed the entire protocol of a three-month Phase 2b clinical trial. The treatment was also associated with reduced levels of MG-driving self-reactive antibodies, but not in the broader antibody…
More than half of adults with generalized myasthenia gravis (gMG) show a clinically meaningful response to Ultomiris (ravulizumab-cwvz) within about two weeks of a first dose, according to a post-hoc analysis of clinical trial data. In contrast, more than 80% of these 139 trial patients experienced a meaningful…
Myasthenia gravis (MG) cases increased gradually from 2000 to 2020 in Denmark, Finland, and Sweden, with the total number of cases and the number of newly diagnosed cases both rising, according to a population-based study. The number of newly diagnosed cases was higher among men older than 50 and…
An artificial intelligence (AI)-powered analysis of more than 11,000 posts on social media or in online community groups found that myasthenia gravis (MG) patients use these platforms primarily to discuss the negative impact of their disease symptoms and their feelings about MG treatments. Most of the posts…
HNSA-5487, an investigational therapy being developed for potential use in myasthenia gravis (MG) and other autoimmune diseases, was safe and rapidly lowered the levels of immunoglobulin G (IgG) antibodies in the bloodstream, according to data from a Phase 1 clinical trial. IgGs are a class of antibodies found in…
A Phase 1 clinical trial for IGM-2644, a potential first-in-class immune T-cell engager therapy for generalized myasthenia gravis (gMG), should begin by the end of the year, said its developer IGM Biosciences. “Our early pivot to using T-cell engagers in autoimmune disease has enabled significant progress on these…
The case of a 72-year-old man who developed myasthenia gravis (MG) and myocarditis, or inflammation of the heart, following chemoimmunotherapy for gastric cancer that included sintilimab showcases the need to better understand how this treatment can induce the immune disorder, said researchers in China. Sintilimab is a type of…
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the skin, or subcutaneously, appears to be as effective as the intravenous treatment Vyvgart (efgartigimod alfa) at reducing IgG antibodies, including those that cause the disease. That’s according to data…
Get regular updates to your inbox.
